Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 12/20 | 0.62 |
| ▸ | DRD2 | P14416 | 7/20 | 0.62 |
| ▸ | DRD3 | P35462 | 2/20 | 0.62 |
| ▸ | DRD4 | P21917 | 1/20 | 0.62 |
| ▸ | DRD5 | P21918 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.56 |
| ▸ | THPO | P40225 | 4/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.56 |
| ▸ | RECQL | P46063 | 3/20 | 0.56 |
| ▸ | TSHR | P16473 | 3/20 | 0.56 |
| ▸ | BLM | P54132 | 3/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.56 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11099766 | 0.84 | DRD1 (0.82) | DRD1DRD2DRD3DRD4DRD5 | |
| Bromide SCHEMBL11496865 | 0.83 | DRD1 (0.82) | DRD1DRD2DRD3DRD4DRD5 | |
| SCHEMBL9161077 | 0.80 | DRD1 (0.55) | DRD1DRD2DRD3DRD4DRD5 | |
| SCHEMBL9162204 | 0.80 | DRD1 (0.55) | DRD1DRD2DRD3DRD4DRD5 | |
| SCHEMBL11243724 | 0.77 | DRD1 (0.72) | DRD1DRD2DRD3DRD4DRD5 | |
| SCHEMBL11273914 | 0.76 | DRD2 (1.00) | DRD1DRD2DRD3DRD4DRD5 | |
| Bromide SCHEMBL11243300 | 0.76 | DRD1 (0.70) | DRD1DRD2DRD3DRD4DRD5 | |
| SCHEMBL34464664 | 0.76 | DRD1 (0.80) | DRD1DRD2DRD3DRD4DRD5 | |
| Bromide SCHEMBL11101325 | 0.76 | DRD2 (0.98) | DRD1DRD2DRD3DRD4DRD5 | |
| SCHEMBL15996611 | 0.76 | DRD1 (0.66) | DRD1DRD2DRD3DRD4DRD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101782-B2 | Drug hybrid of rivastigmine or physostigmine with tranylcypromine, amoxapine, desipramine, nortriptyline, protriptyline, fluoxetine, fluvoxamine, paroxetine, duloxetine, betahistine, amlodipine, proylhexedrine, rimantadine, desloratadine; Alzheimer's disease; Parkinson's disease, impairment in memory | COLUCID PHARMACEUTICALS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-20080261950-A1 | Compounds that inhibit cholinesterase | COLUCID PHARMACEUTICALS, INC. (US) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261950-A1 | Compounds that inhibit cholinesterase | ACHE, BCHE, CHAT | DRD1 1649/4885DRD2 1316/4885DRD3 1679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.